LEXINGTON, Mass., Jan. 14 /PRNewswire/ -- Ardais Corporation today announced that it signed 15 new customers in the fourth quarter, for a total of 40 new customers in 2003, including Biogen Idec, Celera Genomics, Corixa, diaDexus Inc., and Epigenomics. Record orders exceeding $2 million were booked for the company's biomaterials products and services in the fourth quarter. The Company now has commercial agreements with 56 large pharmaceutical and biotechnology customers and has broad-ranging license agreements with five of the top 10 pharmaceutical companies, including AstraZeneca, Aventis, and Bristol-Myers Squibb Company.
"2003 was a turning point for Ardais and for the adoption of our human biomaterials-based approach to improving drug discovery and development," said Michael R. Ball, Ph.D., Vice President, Marketing and Sales, Ardais Corporation. "Researchers now have a system solution available with a broad array of products and services for large-scale drug discovery programs."
Ardais' biomaterials portfolio includes tissue samples with linked clinical information, tissue microarray and molecular derivative products, and immunohistochemistry services launched earlier in the year. The company booked its first European distributor sales through Heidelberg-based, BioCat GmbH.
To augment its biomaterials leadership, Ardais recently launched the proprietary Biospecimen Management System (BMS), a comprehensive set of services and licenses that enable biomedical researchers in pharmaceutical, biotechnology and academic medical research institutions to enroll patients and collect, annotate, manage and distribute their human clinical data and biological material resources. The System is now being deployed at a large academic medical institution, and Ardais has had vigorous interest from more than a dozen other academic medical institutions.
Donald B. Hawthorne, President and CEO, Ardais Corporation, stated, "Since joining Ardais in the fall, I have been very impressed by the exceptional customer feedback on our products and services, and by the growing momentum as the industry increasingly adopts the Ardais approach. We plan to fuel this adoption curve with continued expansion of our portfolio of clinical biomaterials products and services, as well as offering our customized biospecimen management solution on an institutional basis. With this depth and breadth, we are unmatched in the industry, and widely perceived as the partner of choice."
About Ardais Corporation
Ardais Corporation is the leading provider of clinical data and biomaterials resources for molecular medicine and drug discovery and development. The company is dedicated to improving human subjects-based translational research at academic institutions, as well as biotechnology and pharmaceutical companies.
Ardais also offers biospecimen management solutions, encompassing deployment and operational management services, tissue procurement protocols and software, patient enrollment, clinical data collection and quality management systems. Ardais' unique platform addresses ethical, legal and biological concerns and enables biomedical researchers to collect, annotate, manage and distribute their human biological material resources.
Ardais' expanding biomaterials portfolio, sourced from more than 14,000 donors, has more than 180,000 high quality tissue samples, including:
1. Formalin-fixed and frozen samples with associated clinical information
2. Tissue microarrays for high throughput parallel analyses
3. Molecular derivatives, including RNA, DNA and Protein lysates
4. Immunohistochemistry services utilizing both formalin-fixed and frozen
Additional information about Ardais can be found at: http://www.ardais.com/.